Pentagastrin: Mechanism, Dosing & Research Data

Pentagastrin is a synthetic C-terminal pentapeptide of gastrin (gastrin-17 residues 13-17) that contains the minimum sequence required for full gastrin biological activity. It is used as a pharmacological provocateur for gastric acid secretion testing and calcitonin stimulation testing for medullary thyroid carcinoma (MTC) surveillance, though calcitonin stimulation use has largely been replaced by calcium gluconate testing.

Mechanism of Action

CCK2R on gastric parietal cells: Gq/11/PLC/IP3-mediated activation drives H+/K+-ATPase insertion into canalicular membrane and maximal acid secretion
CCK2R on enterochromaffin-like (ECL) cells: stimulates histamine release, which secondarily drives acid secretion via H2 receptors
CCK2R on thyroid C-cells: stimulates calcitonin secretion; used in MTC surveillance to unmask elevated calcitonin in C-cell hyperplasia
Maximum acid output (MAO) stimulated by pentagastrin provides the pharmacological ceiling for acid secretory capacity testing
Structural requirement: the C-terminal Trp-Met-Asp-Phe-NH2 tetrapeptide is the minimal gastrin pharmacophore; beta-Ala extends half-life

Research Findings

Pentagastrin gastric acid test: IV pentagastrin 6 mcg/kg produces MAO; >60 mEq/hour in Zollinger-Ellison syndrome vs <30 mEq/hour normal
MTC surveillance (historical): pentagastrin 0.5 mcg/kg IV caused calcitonin rise >3-fold in C-cell hyperplasia and MTC microcarcinomas with >95% sensitivity
Replaced by calcium gluconate stimulation test: equivalent sensitivity for calcitonin provocation with fewer side effects
Anxiety provocation research: pentagastrin produces panic attacks in patients with panic disorder; used as experimental model to study CCK2R in anxiety
Basic pharmacology: pentagastrin reference agonist established CCK2R selectivity requirements; derived structure-activity relationships led to gastrin/CCK2R drug development

Research Protocols

Gastric acid secretion test: 6 mcg/kg SC or IV; collect gastric aspirate every 15 min for 1 hour; measure MAO by acid titration
MTC surveillance (historical, largely replaced): 0.5 mcg/kg IV bolus; collect blood at 0, 1, 2, 5 minutes; calcitonin rise >3-fold = positive
Research anxiety model: 0.5 mcg/kg IV in anxiety disorder research; provokes panic attacks in susceptible individuals
Not for chronic therapeutic use; diagnostic/research tool only

Interactions

Proton pump inhibitors (omeprazole, pantoprazole): reduce pentagastrin-stimulated acid output; must be withheld before gastric acid testing for valid results
H2 receptor antagonists: reduce pentagastrin acid response via histamine pathway blockade; withhold before testing
CCK2R antagonists (devazepide, proglumide): block pentagastrin responses; used in research to confirm CCK2R mediation

Safety Profile

Short-term diagnostic peptide. Common: nausea, flushing, abdominal cramping, urgency during administration (on-target CCK2R effects). Rare: hypotension, tachycardia. Panic attacks in anxiety-prone individuals. Short duration (<15 min) limits adverse event management. Not for therapeutic use.